Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKLR | P30613 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GCK | P35557 | 1/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL854796 | 0.91 | PKLR (0.63) | PKLRPKMALDH1A1TSHRHSD17B10 | |
| SCHEMBL17861034 | 0.83 | MBTD1 (0.61) | ALDH1A1NPSR1LMNAAKR1C3 | |
| SCHEMBL17860988 | 0.83 | MBTD1 (0.61) | ALDH1A1NPSR1LMNAAKR1C3 | |
| SCHEMBL19457367 | 0.83 | EPHX2 (0.55) | ALDH1A1NPSR1LMNA | |
| SCHEMBL17843469 | 0.83 | MBTD1 (0.61) | ALDH1A1NPSR1LMNAAKR1C3 | |
| SCHEMBL19457361 | 0.83 | EPHX2 (0.55) | ALDH1A1NPSR1LMNA | |
| SCHEMBL2856988 | 0.82 | ALDH1A1 (0.70) | ALDH1A1TSHRNPSR1LMNAAKR1C3 | |
| SCHEMBL21772288 | 0.82 | AKR1C3 (0.54) | PKMALDH1A1TSHRTDP1LMNA | |
| SCHEMBL4514894 | 0.82 | ALDH1A1 (0.54) | PKMALDH1A1LMNA | |
| SCHEMBL2983581 | 0.82 | ALDH1A1 (0.54) | PKMALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | ICAGEN, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7223782-B2 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | SCN3A, TRPV3, HCN3 | PKLR 1556/4885PKM 1321/4885ALDH1A1 3589/4885 |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | SCN3A, TRPV3, HCN3 | PKLR 1556/4885PKM 1321/4885ALDH1A1 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.